Core Insights - The TearCare System by Sight Sciences has been included in the new Dry Eye Workshop (DEWS) III report, which is a significant validation of its clinical efficacy in managing dry eye disease (DED) [1][2] - The DEWS III report is recognized as a primary standard in evidence-based management of DED, highlighting the importance of TearCare in treating meibomian gland disease (MGD) [2][3] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions aimed at transforming patient care and improving lives [4] - The company offers minimally invasive technologies, including the OMNI Surgical System and SION Surgical System, targeting prevalent eye diseases such as glaucoma and dry eye disease [4] Clinical Evidence - The six-month SAHARA randomized controlled trial demonstrated that two treatments with the TearCare system were clinically superior in improving Tear Breakup Time (TBUT) and gland function compared to Restasis, while being non-inferior in Ocular Surface Disease Index (OSDI) [6] - The OLYMPIA randomized controlled trial showed that a single TearCare treatment significantly alleviated signs and symptoms of DED, with greater improvements noted in subjects with more severe disease compared to LipiFlow [6]

Core Insights - The 24-month results from Stage 3 of the SAHARA trial demonstrate significant and sustained improvements in signs and symptoms of dry eye disease for participants treated with the TearCare System [1][3][5] - A majority of participants (66%) required no additional treatment after initial TearCare treatments, indicating the durability of the treatment effect [2][7] Study Results - All mean signs and symptoms remained statistically significantly better than the study baseline at all measured time points up to 24 months [2][5] - Tear breakup time (TBUT) improved from a baseline of 4.41 seconds to a range of 6.29 to 7.13 seconds at Month 24, with p<.0001 indicating strong statistical significance [5] - Meibomian Gland Secretion Score (MGSS) showed sustained improvement from Month 6 (7.26) to Month 24 (means ranging from 17.68 to 18.95), also with p<.0001 [5] - Subjective symptoms assessed by Ocular Surface Disease Index (OSDI), symptom assessment in dry eye (SANDE), and eye dryness score (EDS) remained significantly better than baseline values at all follow-up time points [5][6] Treatment Efficacy - The study confirmed that just two TearCare treatments within five months can lead to meaningful, lasting improvements for up to two years [3][9] - The median time for first retreatment was 7 months, with a 6-month retreatment-free survival probability of 92% [7]